AXS uses $238M of buyback plan to acquire 2.4M shares
Rhea-AI Filing Summary
AXIS Capital Holdings Limited entered into a stock repurchase agreement to buy 2,404,133 common shares from T-VIII PubOpps LP for an aggregate price of approximately $238 million. The seller is an investment vehicle managed by Stone Point Capital, whose Trident Funds held about 3.1% of AXIS’s outstanding common shares, a position that will be reduced to zero after this transaction.
The repurchase is being made under AXIS’s existing Board-authorized $400 million share repurchase program, meaning it uses part of an already approved capital return plan. The filing also notes that director Charles Davis has leadership roles at Stone Point and the Trident Funds, highlighting that this is a sizable, negotiated block repurchase involving a shareholder affiliated with a board member.
Positive
- None.
Negative
- None.
Insights
AXIS executes a large block repurchase from a 3.1% holder.
AXIS Capital Holdings Limited agreed to repurchase 2,404,133 common shares from T-VIII PubOpps LP for about $238,000,000. This transaction is conducted under the company’s existing $400,000,000 share repurchase program, so it represents a substantial use of previously authorized capital to retire a concentrated block of stock.
The seller is linked to Stone Point’s Trident Funds, which held roughly 3.1% of AXIS’s outstanding common shares before the deal and will no longer hold common shares after completion. The filing highlights that director Charles Davis holds senior roles at Stone Point and in the Trident Funds’ governance structure, indicating that this repurchase involves a shareholder affiliated with a board member.
For investors, this block transaction reduces the ownership of a significant institutional holder and uses a meaningful portion of the current repurchase authorization. Actual effects on share count and trading dynamics will depend on AXIS’s broader capital management and any future repurchase or capital allocation decisions disclosed in later periods.